Risk Stratification and Prevention of Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of mortality in developed and developing countries. Beyond modification of risk factors, CVD can also be addressed by treating underlying comorbidities. High-sensitivity cardiac troponin (hs-cTn) testing has been effectively used in the acute setting to manage patients with suspected acute myocardial infarction. Newer research has suggested the incorporation of hs-cTn into existing risk-stratification methods to identify patients with CVD who are candidates for secondary prevention, to influence treatment strategies for those with underlying comormbidities such as atherosclerosis and diabetes, and has evaluated the effectiveness of hs-cTn for primary prevention of cardiovascular conditions in the general population.
In this 60-minute roundtable discussion, faculty will provide a historical perspective on the use of cardiac troponin, evaluate the evolution of high-sensitivity cardiac troponin as a prognostic tool for secondary prevention in high-risk populations with cardiovascular disease, and briefly address the use of hs-cTn in primary prevention as an emerging risk assessment tool in healthy populations.
This activity is intended for cardiologists, emergency medicine physicians, and primary care clinicians (internists, family physicians, nurse practitioners, and physician assistants) throughout Europe and Asia.
At the conclusion of this activity, participants should be better able to:
- Evaluate the use of high-sensitivity cardiac troponin I (hs-cTnI) to refine risk stratification for secondary prevention in patients with CVD and/or diabetes mellitus
- Summarize the data supporting the use of hs-cTnl as a primary prevention tool to predict cardiovascular risk in the general population
David A. Morrow, MD, MPH
Director, Samuel A. Levine Cardiac Unit
Professor of Medicine
Harvard Medical School
Senior Investigator, TIMI Study Group
Dr. Morrow, the TIMI Study Group (Brigham and Women’s Hospital) has received significant grant support from: Abbott Laboratories, Amgen Inc., Anthos Therapeutics, AstraZeneca, Daiichi Sankyo, Inc., Eisai, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corp., Pfizer Inc., Quark Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Roche Diagnostics Corp., Siemens Medical Solutions USA, Inc., Takeda Pharmaceutical Company Limited, Zora Biosciences Oy. Dr. Morrow has been a consultant for/on the advisory board of InCarda Therapeutics, Inc., Merck & Co., Inc., and Roche Diagnostics Corp.
Arshed A. Quyyumi, MD, FRCP
Professor of Medicine, Division of Cardiology
Emory University School of Medicine
Director, Emory Clinical Cardiovascular Research Institute
Bruce Logue Chair for Cardiovascular Research
Dr. Quyyumi has received consulting fees from Caladrius Biosciences, Inc., CardioCel, and FirstMark. He has also been the Primary Investigator and received research grants from Abbott Laboratories, American Heart Association, CSL Behring LLC, Esperion Therapeutics, Inc., Medpace, Inc., Mesoblast Ltd., Morehouse School of Medicine, NIH, NIH National Institute on Aging, and NHLBI.
Dirk Westermann, MD, PhD
Director and Professor
University Medical Center Hamburg
Dr. Westermann has received research funding from Prevencio, Inc. He has received speaker fees from AstraZeneca, Abiomed, The Medicines Company, and Novartis Pharmaceuticals Corp.
All of the relevant financial relationships listed for these individuals have been mitigated.
Accredited Provider Disclosure
None of the planners, reviewers, and Haymarket Medical Education staff for this educational activity have relevant financial relationship(s) with ineligible companies to disclose.
Accredited by Haymarket Medical Education.
In support of improving patient care, Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMA PRA Category 1 CreditTM is generally accepted as equivalent to EACCME credit in Europe through a reciprocity agreement between the American Medical Association and the European Union of Medical Specialists (UEMS).
- 1.00 AMA PRA Category 1 Credit™
This course is offered through myCME.
To take this course you will be redirected to myCME's website. You must login or create an account with myCME in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!